Corcept Therapeutics Inc
CORT71.880USD
-0.130-0.18%
Handelsschluss 07/11, 16:00（ET）Kurse um 15 Minuten verzögert
7.62BMarktkapitalisierung
56.85KGV TTM
mehr Informationen über Corcept Therapeutics Inc Unternehmen
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Unternehmensinformationen
BörsenkürzelCORT
Name des UnternehmensCorcept Therapeutics Inc
IPO-datumApr 15, 2004
Gegründet am1998
CEODr. Joseph K. Belanoff, M.D.
Anzahl der mitarbeiter500
WertpapierartOrdinary Share
GeschäftsjahresendeApr 15
Addresse101 Redwood Shores Parkway
StadtREDWOOD CITY
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94065
Telefon16506888803
Websitehttps://www.corcept.com/
BörsenkürzelCORT
IPO-datumApr 15, 2004
Gegründet am1998
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
Mr. Atabak Mokari
Mr. Atabak Mokari
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.06K
+7.91%
Mr. Joseph Douglas Lyon
Mr. Joseph Douglas Lyon
Chief Accounting and Technology Officer
Chief Accounting and Technology Officer
10.07K
--
Mr. William Guyer, Pharm.D.
Mr. William Guyer, Pharm.D.
Chief Development Officer
Chief Development Officer
5.49K
--
Mr. Gregg Huber Alton, J.D.
Mr. Gregg Huber Alton, J.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
35.90%
Investment Advisor
31.21%
Individual Investor
11.55%
Hedge Fund
8.44%
Research Firm
1.58%
Pension Fund
1.03%
Sovereign Wealth Fund
0.82%
Bank and Trust
0.51%
Family Office
0.06%
Other
8.89%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
722
96.66M
91.15%
-8.10M
2025Q1
746
97.45M
92.10%
-9.12M
2024Q4
673
98.29M
93.20%
-10.89M
2024Q3
625
101.82M
97.42%
-10.51M
2024Q2
589
103.22M
99.09%
-12.69M
2024Q1
582
107.51M
103.94%
+2.98M
2023Q4
555
98.31M
95.40%
-4.22M
2023Q3
540
96.45M
94.14%
-5.68M
2023Q2
523
94.35M
92.83%
-12.18M
2023Q1
528
100.60M
93.30%
-751.20K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
13.02M
12.28%
-611.02K
-4.48%
Mar 31, 2025
The Vanguard Group, Inc.
9.96M
9.39%
-133.66K
-1.32%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
7.74M
7.3%
-357.16K
-4.41%
Mar 31, 2025
Renaissance Technologies LLC
6.14M
5.79%
-55.57K
-0.90%
Mar 31, 2025
Baker (George Leonard Jr.)
5.31M
5.01%
--
--
Apr 17, 2025
Parallel Advisors, LLC
3.97M
3.75%
+142.78K
+3.73%
Mar 31, 2025
State Street Global Advisors (US)
3.40M
3.21%
-146.42K
-4.13%
Mar 31, 2025
Belanoff (Joseph K)
2.98M
2.81%
-40.35K
-1.34%
Apr 17, 2025
Wilson (James N)
2.35M
2.21%
+129.14K
+5.82%
Apr 17, 2025
Geode Capital Management, L.L.C.
2.26M
2.13%
+191.89K
+9.28%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
SPDR S&P Pharmaceuticals ETF
5.35%
Invesco S&P SmallCap Health Care ETF
5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
4.73%
Formidable ETF
4.13%
Invesco Pharmaceuticals ETF
3.79%
First Trust NYSE Arca Biotechnology Index Fund
3.55%
iShares U.S. Pharmaceuticals ETF
3.46%
Invesco S&P SmallCap Momentum ETF
3.09%
Invesco S&P SmallCap Quality ETF
2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
1.9%
Mehr Anzeigen
SPDR S&P Pharmaceuticals ETF
Anteil5.35%
Invesco S&P SmallCap Health Care ETF
Anteil5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil4.73%
Formidable ETF
Anteil4.13%
Invesco Pharmaceuticals ETF
Anteil3.79%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.55%
iShares U.S. Pharmaceuticals ETF
Anteil3.46%
Invesco S&P SmallCap Momentum ETF
Anteil3.09%
Invesco S&P SmallCap Quality ETF
Anteil2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
Anteil1.9%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
